Neurological Biomarkers Market Size, Trends, Analysis, and Outlook By Type (Genomic, Proteomic, Metabolomic, Imaging, Others), By Application (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder, Others), By End-user (Hospital & Hospital Laboratories, Independent clinical diagnostic centers, Research Organizations, Others), by Region, Country, Segment, and Companies, 2024-2030
The global Neurological Biomarkers market size is poised to register 14.63% growth from 2024 to 2030, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Neurological Biomarkers market across By Type (Genomic, Proteomic, Metabolomic, Imaging, Others), By Application (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder, Others), By End-user (Hospital & Hospital Laboratories, Independent clinical diagnostic centers, Research Organizations, Others).
The Neurological Biomarkers market is experiencing significant growth driven by increasing research in neuroscience, growing demand for personalized medicine, and advancements in biomarker discovery technologies. Neurological biomarkers are measurable indicators found in blood, cerebrospinal fluid, or imaging scans that provide information about the presence, progression, or response to treatment of neurological disorders such as Alzheimer's disease, multiple sclerosis, and stroke. Factors such as the rising prevalence of neurological disorders, the need for early and accurate diagnosis, and the development of novel biomarker assays and imaging modalities are driving market expansion. Additionally, advancements in omics technologies such as genomics, proteomics, and metabolomics, along with the identification of disease-specific biomarker signatures, are fueling innovation in the market. Moreover, the increasing adoption of biomarker-based diagnostic tests and companion diagnostics in clinical trials and routine clinical practice, along with the integration of artificial intelligence (AI) and machine learning algorithms for biomarker data analysis, are driving market growth. Furthermore, efforts to validate and standardize biomarker assays, establish biomarker panels for disease subtyping and prognosis prediction, and address regulatory and reimbursement challenges are expected to further propel market growth in the coming years.
Neurological Biomarkers Market Drivers, Trends, Opportunities, and Growth Opportunities
This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Neurological Biomarkers market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Neurological Biomarkers survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Neurological Biomarkers industry.
Key market trends defining the global Neurological Biomarkers demand in 2024 and Beyond
The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.
Neurological Biomarkers Market Segmentation- Industry Share, Market Size, and Outlook to 2030
The Neurological Biomarkers industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Neurological Biomarkers companies scaling up production in these sub-segments with a focus on expanding into emerging countries.
Key strategies adopted by companies within the Neurological Biomarkers industry
Leading Neurological Biomarkers companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Neurological Biomarkers companies.
Neurological Biomarkers Market Study- Strategic Analysis Review
The Neurological Biomarkers market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-
The Neurological Biomarkers industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.
Neurological Biomarkers Country Analysis and Revenue Outlook to 2030
The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.
North America Neurological Biomarkers Market Size Outlook- Companies plan for focused investments in a changing environment
The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Neurological Biomarkers market segments. Similarly, Strong end-user demand is encouraging Canadian Neurological Biomarkers companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Neurological Biomarkers market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.
Europe Neurological Biomarkers Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities
The German industry remains the major market for companies in the European Neurological Biomarkers industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Neurological Biomarkers market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.
Asia Pacific Neurological Biomarkers Market Size Outlook- an attractive hub for opportunities for both local and global companies
The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Neurological Biomarkers in Asia Pacific. In particular, China, India, and South East Asian Neurological Biomarkers markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.
Latin America Neurological Biomarkers Market Size Outlook- Continued urbanization and rising income levels
Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.
Middle East and Africa Neurological Biomarkers Market Size Outlook- continues its upward trajectory across segments
Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Neurological Biomarkers market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Neurological Biomarkers.
Neurological Biomarkers Market Company Profiles
The global Neurological Biomarkers market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are Abbott, Thermo Fisher Scientific, Inc., Merck & Co., Inc., Bio-Rad Laboratories, Inc., Johnson & Johnson Services, Inc., DiaGenic ASA, Banyan Biomarkers, Inc., Quanterix, Alseres Pharmaceuticals, Inc., Rules-Based Medicine
Recent Neurological Biomarkers Market Developments
The global Neurological Biomarkers market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.
Neurological Biomarkers Market Report Scope
Parameters: Revenue, Volume Price
Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)
Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)
Qualitative Analysis
By Type
Genomic
Proteomic
Metabolomic
Imaging
Others
By Application
Alzheimer's Disease
Parkinson's Disease
Multiple Sclerosis
Autism Spectrum Disorder
Others
By End-user
Hospital & Hospital Laboratories
Independent clinical diagnostic centers
Research Organizations
Others
Geographical Segmentation:
Abbott
Thermo Fisher Scientific, Inc.
Merck & Co., Inc.
Bio-Rad Laboratories, Inc.
Johnson & Johnson Services, Inc.
DiaGenic ASA
Banyan Biomarkers, Inc.
Quanterix
Alseres Pharmaceuticals, Inc.
Rules-Based Medicine
Formats Available: Excel, PDF, and PPT
The Neurological Biomarkers market is experiencing significant growth driven by increasing research in neuroscience, growing demand for personalized medicine, and advancements in biomarker discovery technologies. Neurological biomarkers are measurable indicators found in blood, cerebrospinal fluid, or imaging scans that provide information about the presence, progression, or response to treatment of neurological disorders such as Alzheimer's disease, multiple sclerosis, and stroke. Factors such as the rising prevalence of neurological disorders, the need for early and accurate diagnosis, and the development of novel biomarker assays and imaging modalities are driving market expansion. Additionally, advancements in omics technologies such as genomics, proteomics, and metabolomics, along with the identification of disease-specific biomarker signatures, are fueling innovation in the market. Moreover, the increasing adoption of biomarker-based diagnostic tests and companion diagnostics in clinical trials and routine clinical practice, along with the integration of artificial intelligence (AI) and machine learning algorithms for biomarker data analysis, are driving market growth. Furthermore, efforts to validate and standardize biomarker assays, establish biomarker panels for disease subtyping and prognosis prediction, and address regulatory and reimbursement challenges are expected to further propel market growth in the coming years.
Neurological Biomarkers Market Drivers, Trends, Opportunities, and Growth Opportunities
This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Neurological Biomarkers market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Neurological Biomarkers survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Neurological Biomarkers industry.
Key market trends defining the global Neurological Biomarkers demand in 2024 and Beyond
The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.
Neurological Biomarkers Market Segmentation- Industry Share, Market Size, and Outlook to 2030
The Neurological Biomarkers industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Neurological Biomarkers companies scaling up production in these sub-segments with a focus on expanding into emerging countries.
Key strategies adopted by companies within the Neurological Biomarkers industry
Leading Neurological Biomarkers companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Neurological Biomarkers companies.
Neurological Biomarkers Market Study- Strategic Analysis Review
The Neurological Biomarkers market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-
- Industry Dynamics: Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.
- Strategic Insights: Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.
- Internal Strengths and Weaknesses: Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.
- Future Possibilities: Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.
The Neurological Biomarkers industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.
Neurological Biomarkers Country Analysis and Revenue Outlook to 2030
The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.
North America Neurological Biomarkers Market Size Outlook- Companies plan for focused investments in a changing environment
The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Neurological Biomarkers market segments. Similarly, Strong end-user demand is encouraging Canadian Neurological Biomarkers companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Neurological Biomarkers market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.
Europe Neurological Biomarkers Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities
The German industry remains the major market for companies in the European Neurological Biomarkers industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Neurological Biomarkers market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.
Asia Pacific Neurological Biomarkers Market Size Outlook- an attractive hub for opportunities for both local and global companies
The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Neurological Biomarkers in Asia Pacific. In particular, China, India, and South East Asian Neurological Biomarkers markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.
Latin America Neurological Biomarkers Market Size Outlook- Continued urbanization and rising income levels
Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.
Middle East and Africa Neurological Biomarkers Market Size Outlook- continues its upward trajectory across segments
Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Neurological Biomarkers market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Neurological Biomarkers.
Neurological Biomarkers Market Company Profiles
The global Neurological Biomarkers market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are Abbott, Thermo Fisher Scientific, Inc., Merck & Co., Inc., Bio-Rad Laboratories, Inc., Johnson & Johnson Services, Inc., DiaGenic ASA, Banyan Biomarkers, Inc., Quanterix, Alseres Pharmaceuticals, Inc., Rules-Based Medicine
Recent Neurological Biomarkers Market Developments
The global Neurological Biomarkers market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.
Neurological Biomarkers Market Report Scope
Parameters: Revenue, Volume Price
Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)
Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)
Qualitative Analysis
- Pricing Analysis
- Value Chain Analysis
- SWOT Profile
- Market Dynamics- Trends, Drivers, Challenges
- Porter’s Five Forces Analysis
- Macroeconomic Impact Analysis
- Case Scenarios- Low, Base, High
By Type
Genomic
Proteomic
Metabolomic
Imaging
Others
By Application
Alzheimer's Disease
Parkinson's Disease
Multiple Sclerosis
Autism Spectrum Disorder
Others
By End-user
Hospital & Hospital Laboratories
Independent clinical diagnostic centers
Research Organizations
Others
Geographical Segmentation:
- North America (3 markets)
- Europe (6 markets)
- Asia Pacific (6 markets)
- Latin America (3 markets)
- Middle East Africa (5 markets)
Abbott
Thermo Fisher Scientific, Inc.
Merck & Co., Inc.
Bio-Rad Laboratories, Inc.
Johnson & Johnson Services, Inc.
DiaGenic ASA
Banyan Biomarkers, Inc.
Quanterix
Alseres Pharmaceuticals, Inc.
Rules-Based Medicine
Formats Available: Excel, PDF, and PPT
1. EXECUTIVE SUMMARY
1.1 Neurological Biomarkers Market Overview and Key Findings, 2024
1.2 Neurological Biomarkers Market Size and Growth Outlook, 2021- 2030
1.3 Neurological Biomarkers Market Growth Opportunities to 2030
1.4 Key Neurological Biomarkers Market Trends and Challenges
1.4.1 Neurological Biomarkers Market Drivers and Trends
1.4.2 Neurological Biomarkers Market Challenges
1.5 Competitive Landscape and Key Players
1.6 Competitive Analysis- Growth Strategies Adopted by Leading Neurological Biomarkers Companies
2. NEUROLOGICAL BIOMARKERS MARKET SIZE OUTLOOK TO 2030
2.1 Neurological Biomarkers Market Size Outlook, USD Million, 2021- 2030
2.2 Neurological Biomarkers Incremental Market Growth Outlook, %, 2021- 2030
2.3 Segment Snapshot, 2024
3. NEUROLOGICAL BIOMARKERS MARKET- STRATEGIC ANALYSIS REVIEW
3.1 Porter's Five Forces Analysis
* Threat of New Entrants
* Threat of Substitutes
* Intensity of Competitive Rivalry
* Bargaining Power of Buyers
* Bargaining Power of Suppliers
3.2 Value Chain Analysis
3.3 SWOT Analysis
4. NEUROLOGICAL BIOMARKERS MARKET SEGMENTATION ANALYSIS AND OUTLOOK
4.1 Market Segmentation and Scope
4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
By Type
Genomic
Proteomic
Metabolomic
Imaging
Others
By Application
Alzheimer's Disease
Parkinson's Disease
Multiple Sclerosis
Autism Spectrum Disorder
Others
By End-user
Hospital & Hospital Laboratories
Independent clinical diagnostic centers
Research Organizations
Others
4.3 Growth Prospects and Niche Opportunities, 2023- 2030
4.4 Regional comparison of Market Growth, CAGR, 2023-2030
5. REGION-WISE MARKET OUTLOOK TO 2030
5.1 Key Findings for Asia Pacific Neurological Biomarkers Market, 2025
5.2 Asia Pacific Neurological Biomarkers Market Size Outlook by Type, 2021- 2030
5.3 Asia Pacific Neurological Biomarkers Market Size Outlook by Application, 2021- 2030
5.4 Key Findings for Europe Neurological Biomarkers Market, 2025
5.5 Europe Neurological Biomarkers Market Size Outlook by Type, 2021- 2030
5.6 Europe Neurological Biomarkers Market Size Outlook by Application, 2021- 2030
5.7 Key Findings for North America Neurological Biomarkers Market, 2025
5.8 North America Neurological Biomarkers Market Size Outlook by Type, 2021- 2030
5.9 North America Neurological Biomarkers Market Size Outlook by Application, 2021- 2030
5.10 Key Findings for South America Neurological Biomarkers Market, 2025
5.11 South America Pacific Neurological Biomarkers Market Size Outlook by Type, 2021- 2030
5.12 South America Neurological Biomarkers Market Size Outlook by Application, 2021- 2030
5.13 Key Findings for Middle East and Africa Neurological Biomarkers Market, 2025
5.14 Middle East Africa Neurological Biomarkers Market Size Outlook by Type, 2021- 2030
5.15 Middle East Africa Neurological Biomarkers Market Size Outlook by Application, 2021- 2030
6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030
6.1 US Neurological Biomarkers Market Size Outlook and Revenue Growth Forecasts
6.2 US Neurological Biomarkers Industry Drivers and Opportunities
6.3 Canada Market Size Outlook and Revenue Growth Forecasts
6.4 Canada Neurological Biomarkers Industry Drivers and Opportunities
6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
6.6 Mexico Neurological Biomarkers Industry Drivers and Opportunities
6.7 Germany Market Size Outlook and Revenue Growth Forecasts
6.8 Germany Neurological Biomarkers Industry Drivers and Opportunities
6.9 France Market Size Outlook and Revenue Growth Forecasts
6.10 France Neurological Biomarkers Industry Drivers and Opportunities
6.11 UK Market Size Outlook and Revenue Growth Forecasts
6.12 UK Neurological Biomarkers Industry Drivers and Opportunities
6.13 Spain Market Size Outlook and Revenue Growth Forecasts
6.14 Spain Neurological Biomarkers Industry Drivers and Opportunities
6.16 Italy Market Size Outlook and Revenue Growth Forecasts
6.16 Italy Neurological Biomarkers Industry Drivers and Opportunities
6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
6.18 Rest of Europe Neurological Biomarkers Industry Drivers and Opportunities
6.19 China Market Size Outlook and Revenue Growth Forecasts
6.20 China Neurological Biomarkers Industry Drivers and Opportunities
6.21 India Market Size Outlook and Revenue Growth Forecasts
6.22 India Neurological Biomarkers Industry Drivers and Opportunities
6.23 Japan Market Size Outlook and Revenue Growth Forecasts
6.24 Japan Neurological Biomarkers Industry Drivers and Opportunities
6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
6.26 South Korea Neurological Biomarkers Industry Drivers and Opportunities
6.27 Australia Market Size Outlook and Revenue Growth Forecasts
6.28 Australia Neurological Biomarkers Industry Drivers and Opportunities
6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
6.30 South East Asia Neurological Biomarkers Industry Drivers and Opportunities
6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
6.32 Rest of Asia Pacific Neurological Biomarkers Industry Drivers and Opportunities
6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
6.34 Brazil Neurological Biomarkers Industry Drivers and Opportunities
6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
6.36 Argentina Neurological Biomarkers Industry Drivers and Opportunities
6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
6.38 Rest of South America Neurological Biomarkers Industry Drivers and Opportunities
6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
6.40 Middle East Neurological Biomarkers Industry Drivers and Opportunities
6.41 Africa Market Size Outlook and Revenue Growth Forecasts
6.42 Africa Neurological Biomarkers Industry Drivers and Opportunities
7. NEUROLOGICAL BIOMARKERS MARKET OUTLOOK ACROSS SCENARIOS
7.1 Low Growth Case
7.2 Reference Growth Case
7.3 High Growth Case
8. NEUROLOGICAL BIOMARKERS COMPANY PROFILES
8.1 Profiles of Leading Neurological Biomarkers Companies in the Market
8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
8.3 Financial Performance and Key Metrics
Abbott
Thermo Fisher Scientific, Inc.
Merck & Co., Inc.
Bio-Rad Laboratories, Inc.
Johnson & Johnson Services, Inc.
DiaGenic ASA
Banyan Biomarkers, Inc.
Quanterix
Alseres Pharmaceuticals, Inc.
Rules-Based Medicine
9. APPENDIX
9.1 Scope of the Report
9.2 Research Methodology and Data Sources
9.3 Glossary of Terms
9.4 Market Definitions
9.5 Contact Information
1.1 Neurological Biomarkers Market Overview and Key Findings, 2024
1.2 Neurological Biomarkers Market Size and Growth Outlook, 2021- 2030
1.3 Neurological Biomarkers Market Growth Opportunities to 2030
1.4 Key Neurological Biomarkers Market Trends and Challenges
1.4.1 Neurological Biomarkers Market Drivers and Trends
1.4.2 Neurological Biomarkers Market Challenges
1.5 Competitive Landscape and Key Players
1.6 Competitive Analysis- Growth Strategies Adopted by Leading Neurological Biomarkers Companies
2. NEUROLOGICAL BIOMARKERS MARKET SIZE OUTLOOK TO 2030
2.1 Neurological Biomarkers Market Size Outlook, USD Million, 2021- 2030
2.2 Neurological Biomarkers Incremental Market Growth Outlook, %, 2021- 2030
2.3 Segment Snapshot, 2024
3. NEUROLOGICAL BIOMARKERS MARKET- STRATEGIC ANALYSIS REVIEW
3.1 Porter's Five Forces Analysis
* Threat of New Entrants
* Threat of Substitutes
* Intensity of Competitive Rivalry
* Bargaining Power of Buyers
* Bargaining Power of Suppliers
3.2 Value Chain Analysis
3.3 SWOT Analysis
4. NEUROLOGICAL BIOMARKERS MARKET SEGMENTATION ANALYSIS AND OUTLOOK
4.1 Market Segmentation and Scope
4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
By Type
Genomic
Proteomic
Metabolomic
Imaging
Others
By Application
Alzheimer's Disease
Parkinson's Disease
Multiple Sclerosis
Autism Spectrum Disorder
Others
By End-user
Hospital & Hospital Laboratories
Independent clinical diagnostic centers
Research Organizations
Others
4.3 Growth Prospects and Niche Opportunities, 2023- 2030
4.4 Regional comparison of Market Growth, CAGR, 2023-2030
5. REGION-WISE MARKET OUTLOOK TO 2030
5.1 Key Findings for Asia Pacific Neurological Biomarkers Market, 2025
5.2 Asia Pacific Neurological Biomarkers Market Size Outlook by Type, 2021- 2030
5.3 Asia Pacific Neurological Biomarkers Market Size Outlook by Application, 2021- 2030
5.4 Key Findings for Europe Neurological Biomarkers Market, 2025
5.5 Europe Neurological Biomarkers Market Size Outlook by Type, 2021- 2030
5.6 Europe Neurological Biomarkers Market Size Outlook by Application, 2021- 2030
5.7 Key Findings for North America Neurological Biomarkers Market, 2025
5.8 North America Neurological Biomarkers Market Size Outlook by Type, 2021- 2030
5.9 North America Neurological Biomarkers Market Size Outlook by Application, 2021- 2030
5.10 Key Findings for South America Neurological Biomarkers Market, 2025
5.11 South America Pacific Neurological Biomarkers Market Size Outlook by Type, 2021- 2030
5.12 South America Neurological Biomarkers Market Size Outlook by Application, 2021- 2030
5.13 Key Findings for Middle East and Africa Neurological Biomarkers Market, 2025
5.14 Middle East Africa Neurological Biomarkers Market Size Outlook by Type, 2021- 2030
5.15 Middle East Africa Neurological Biomarkers Market Size Outlook by Application, 2021- 2030
6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030
6.1 US Neurological Biomarkers Market Size Outlook and Revenue Growth Forecasts
6.2 US Neurological Biomarkers Industry Drivers and Opportunities
6.3 Canada Market Size Outlook and Revenue Growth Forecasts
6.4 Canada Neurological Biomarkers Industry Drivers and Opportunities
6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
6.6 Mexico Neurological Biomarkers Industry Drivers and Opportunities
6.7 Germany Market Size Outlook and Revenue Growth Forecasts
6.8 Germany Neurological Biomarkers Industry Drivers and Opportunities
6.9 France Market Size Outlook and Revenue Growth Forecasts
6.10 France Neurological Biomarkers Industry Drivers and Opportunities
6.11 UK Market Size Outlook and Revenue Growth Forecasts
6.12 UK Neurological Biomarkers Industry Drivers and Opportunities
6.13 Spain Market Size Outlook and Revenue Growth Forecasts
6.14 Spain Neurological Biomarkers Industry Drivers and Opportunities
6.16 Italy Market Size Outlook and Revenue Growth Forecasts
6.16 Italy Neurological Biomarkers Industry Drivers and Opportunities
6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
6.18 Rest of Europe Neurological Biomarkers Industry Drivers and Opportunities
6.19 China Market Size Outlook and Revenue Growth Forecasts
6.20 China Neurological Biomarkers Industry Drivers and Opportunities
6.21 India Market Size Outlook and Revenue Growth Forecasts
6.22 India Neurological Biomarkers Industry Drivers and Opportunities
6.23 Japan Market Size Outlook and Revenue Growth Forecasts
6.24 Japan Neurological Biomarkers Industry Drivers and Opportunities
6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
6.26 South Korea Neurological Biomarkers Industry Drivers and Opportunities
6.27 Australia Market Size Outlook and Revenue Growth Forecasts
6.28 Australia Neurological Biomarkers Industry Drivers and Opportunities
6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
6.30 South East Asia Neurological Biomarkers Industry Drivers and Opportunities
6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
6.32 Rest of Asia Pacific Neurological Biomarkers Industry Drivers and Opportunities
6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
6.34 Brazil Neurological Biomarkers Industry Drivers and Opportunities
6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
6.36 Argentina Neurological Biomarkers Industry Drivers and Opportunities
6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
6.38 Rest of South America Neurological Biomarkers Industry Drivers and Opportunities
6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
6.40 Middle East Neurological Biomarkers Industry Drivers and Opportunities
6.41 Africa Market Size Outlook and Revenue Growth Forecasts
6.42 Africa Neurological Biomarkers Industry Drivers and Opportunities
7. NEUROLOGICAL BIOMARKERS MARKET OUTLOOK ACROSS SCENARIOS
7.1 Low Growth Case
7.2 Reference Growth Case
7.3 High Growth Case
8. NEUROLOGICAL BIOMARKERS COMPANY PROFILES
8.1 Profiles of Leading Neurological Biomarkers Companies in the Market
8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
8.3 Financial Performance and Key Metrics
Abbott
Thermo Fisher Scientific, Inc.
Merck & Co., Inc.
Bio-Rad Laboratories, Inc.
Johnson & Johnson Services, Inc.
DiaGenic ASA
Banyan Biomarkers, Inc.
Quanterix
Alseres Pharmaceuticals, Inc.
Rules-Based Medicine
9. APPENDIX
9.1 Scope of the Report
9.2 Research Methodology and Data Sources
9.3 Glossary of Terms
9.4 Market Definitions
9.5 Contact Information
